Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Marriott Wardman Park Hotel

Jan 27, 2020 1:00 PM - Jan 29, 2020 10:15 PM

2660 Woodley Road, NW, , Washington, DC 20008 , USA

Pharmacovigilance and Risk Management Strategies Conference


January 26: Short Courses
January 27-29: Conference

DIA's Pharmacovigilance and Risk Management Strategies Conference provides the foundation for strong strategic planning and practical decision-making in your pharmacovigilance programs. Developed by recognized experts from the biopharmaceutical industry and global regulatory agencies, this conference provides the background, context, and opportunities to discuss current challenges and to problem-solve around issues that matter most to professionals working in the field.

This year’s conference will address the current thinking on predicting and assessing risks such as drug-induced liver injury, and the assessment of expectedness of serious adverse reactions during clinical development. The complexities of assessing benefit-risk balance of today’s therapies, including immunotherapy and other advanced therapies, will be examined. Experts will present approaches and engage in dialogs around more extensive and impactful uses of real world data and generation of RWE for safety assessments. A full-day will be devoted to the development, implementation, and assessment of risk management strategies for drugs approved in multiple regions, with a special in-depth coverage of REMS in the US.

In addition to new developments and updates on regional regulations and guidelines, regulators from the US, EU, and other global regions provide the context and thinking behind evolving requirements.

"One of the best conferences I have attended. A broad view on how far we have come in the world of PV, why we do what we do, and what is still to come ot meet future needs of patients and managing benefit-risk." - Mary Welke, Trilogy Writing & Consulting, Inc

Pharmacovigilance and Risk Management in 2020: A Global Perspective

With the development of expedited regulatory frameworks in the US, EU, and Japan to address unmet medical needs, traditional clinical safety and pharmacovigilance methods must adapt. Download our exclusive eBook to learn more about international and regional initiatives impacting Pharmacovigilance in 2020.

Download eBook.

Featured topics

  • Real World Evidence – Regulatory agency perspectives on the use of RWE for safety assessments
  • RWE – Next generation approaches for expanding the use of RWE in safety decision-making
  • ICH and CIOMS new safety projects and their expected impact on safety and pharmacovigilance: ICH E19 Expert Working Group (Optimisation of Safety Data Collection), CIOMS Working Group XI (Patient Involvement), CIOMS MedDRA Labelling Groupings (MLGs), and discussion of the ICH E2D Guideline (Post-Approval Safety Data Management)
  • Drug Induced Liver Injury (DILI) – current research on the mechanisms of injury and the ability to predict DILI from non-clinical and clinical research
  • Special considerations in benefit-risk assessment of immune-oncology therapies


Want to learn more about Pharmacovigilance and Risk Management Strategies Conference? You've come to the right site!

Continuing Education


Highlights & Features

Who should attend?

Professionals with intermediate to advanced knowledge of, and experience in, clinical safety and who are involved in:

  • Drug Safety/Pharmacovigilance
  • Risk Management, including Risk Evaluation and Mitigation Strategies (REMS)
  • Benefit-Risk Assessment and Communication
  • Medical Product Safety Assessment
  • Regulatory Affairs
  • Clinical Research
  • Pharmacoepidemiology
  • Post-Market Studies and Real World Evidence Generation
  • Customer Engagement Programs, including Patient Support Programs
  • Medical Information, Medical Communications
  • Health Outcomes

It is also designed for professionals who work for:

  • Industry: Pharmaceuticals, Biologics, Combination Products, Devices
  • Clinical Research Organizations, Contract Service Organizations
  • Academic Research Centers
  • Regulatory Agencies
  • Government Research Programs

Learning objectives

At the conclusion of this conference, participants should be able to:
  • Apply the current regulatory framework for pharmacovigilance in key markets, including the US and the changing EU
  • Discuss the impact of current pharmacovigilance conditions, regulatory requirements, and recent developments in India, China, and Japan on safety and pharmacovigilance practice in those markets
  • Describe new ICH and CIOMS pharmacovigilance projects underway and their importance to evolving best practices in patient engagement and safety data collection
  • Discuss current research findings on mechanisms of risk such as drug-induced liver injury (DILI) and their impact on assessing benefit-risk associated with therapies, including new and advanced therapies
  • Compare and contrast risk management tools, such as REMS and RMPs, approved by various regulatory agencies; and discuss risk management strategies that have achieved successful implementation in a complex global setting
  • Explain new approaches for surveilling medication errors and effective methods to prevent and reduce these errors
  • Describe new approaches and opportunities to use RWE for safety assessment and evidence generation

Short Course or Primer

To keep you at the forefront.

Jan 26, 2020

Short Course 1:

Pharmacovigilance and Risk Management Planning

Jan 26, 2020

Short Course 2:

Interdisciplinary Safety Evaluation During Product Development

Jan 26, 2020

Short Course 3:

Reference Safety Information

Jan 26, 2020

Short Course 4:

Introduction to Statistics in Pharmacovigilance

Jan 26, 2020

Short Course 5:

Pharmacovigilance for Medication Errors

Program Committee

  • Stella  Blackburn, MD, MA, MSc, FFPM, FISPE, FRCP
    Stella Blackburn, MD, MA, MSc, FFPM, FISPE, FRCP Strategy
    Consultant, United Kingdom
  • William  Gregory, PhD
    William Gregory, PhD Senior Director, Safety and Risk Management
    Pfizer Inc, United States
  • Catherine  Baldridge, MSc
    Catherine Baldridge, MSc Head of Safety
    Fusion Pharmaceuticals, United States
  • Mariette  Boerstoel-Streefland, MD, MBA, MS
    Mariette Boerstoel-Streefland, MD, MBA, MS Senior Vice President, Worldwide Safety Officer
    Bristol-Myers Squibb Company, United States
  • Cheryl  Campbell, MS
    Cheryl Campbell, MS Associate Director of Executive Operations/Outreach and Communications, OSE,CDER
    FDA, United States
  • Ingrid N. Chapman, PharmD
    Ingrid N. Chapman, PharmD Senior Risk Management Analyst, DRM, OMEPRM, OSE, CDER
    FDA, United States
  • Mick  Foy
    Mick Foy Director of Delivery
    Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
  • E. Stewart  Geary, MD
    E. Stewart Geary, MD Senior Vice President
    Eisai Co., Ltd., Japan
  • Stephen  Knowles, MD, MRCP
    Stephen Knowles, MD, MRCP Chief Medical Officer
    Halozyme Therapeutics, United States
  • Jill K. Logan, PharmD
    Jill K. Logan, PharmD Safety Evaluator, DPV I, OSE, CDER
    FDA, United States
  • Barbara  Morollo, RN
    Barbara Morollo, RN Head, Pharmacovigilance
    Corbus Pharmaceuticals, United States
  • Michael  Richardson, MD, FFPM, FRCP
    Michael Richardson, MD, FFPM, FRCP Senior Vice President, WorldWide Patient Safety
    Bristol-Myers Squibb, United Kingdom
  • Annette  Stemhagen, DrPH, PhD, FISPE
    Annette Stemhagen, DrPH, PhD, FISPE Chief Science Officer
    UBC, United States
  • Lesley  Wise, PhD, MSc
    Lesley Wise, PhD, MSc Managing Director
    Wise Pharmacovigilance and Risk Management, Ltd, United Kingdom
  • Hui-Lee  Wong, PhD, MS
    Hui-Lee Wong, PhD, MS Epidemiologist, Sentinel Central Team, OBE, CBER
    FDA, United States
  • Jo  Wyeth, PharmD
    Jo Wyeth, PharmD Associate Director for Postmarket Assessments, OMEPRM, OSE, CDER
    FDA, United States

Digital Learning Catalog

DIA Learning: eLearning Soultions

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.